Sulfafurazole


Concise Prescribing Info
Indications/Uses
Susceptible infections.
Dosage/Direction for Use
Adult : PO Initial: 2-4 g, then 4-8 g/day in divided doses 4-6 hrly.
Dosage Details
Oral
Chlamydial infections, Chlamydial pneumonia, Lymphogranuloma venereum, Nocardiosis, Otitis media, Trachoma, Urinary tract infections
Adult: Initially, 2-4 g followed by 4-8 g/day in divided doses every 4-6 hr.
Child: >2 mth: Initially, 75 mg/kg followed by 150 mg/kg/day in divided doses. Max: 6 g daily.
Renal Impairment
Dose adjustment may be needed. Severe: Contraindicated.
Hepatic Impairment
Dose adjustment may be needed. Severe: Contraindicated.
Administration
May be taken with or without food. May be taken w/ meals to reduce GI discomfort.
Contraindications
Severe renal or hepatic failure; blood disorders; hypersensitivity to sulfonamides; acute porphyria. Pregnancy (3rd trimester) ; infants ≤2 mth.
Special Precautions
Renal or hepatic impairment; history of allergy or asthma; AIDS; G6PD deficiency; elderly; ensure adequate fluid intake to reduce risk of crystalluria; SLE. Lactation.
Adverse Reactions
Nausea, vomiting, anorexia, diarrhoea, hypersensitivity reactions, SLE, serum sickness-like syndrome, liver necrosis, hepatomegaly, myocarditis, pulmonary eosinophilia and fibrosing alveolitis, vasculitis, hypoglycaemia, hypothyroidism, neurological reactions, jaundice and kernicterus in premature neonates.
Potentially Fatal: Blood dyscrasias, Stevens-Johnson syndrome, toxic epidermal necrolysis, anaphylaxis.
Drug Interactions
Potentiates effects of oral anticoagulants, methotrexate, phenytoin. Increased anaesthetic effect of thiopental. Increased risk of crytalluria with compounds that render the urine acidic.
Lab Interference
Interference with tests for urea, creatinine, urinary glucose, urobilinogen.
Action
Description: Sulfafurazole is a short-acting sulfonamide also known as sulfisoxazole. It interferes with the synthesis of nucleic acids in sensitive organisms by blocking the conversion of p-aminobenzoic acid (PABA) to the co-enzyme dihydrofolic acid. Its action is bacteriostatic, although it can be bactericidal where concentrations of thymine are low in the surrounding medium.
Pharmacokinetics:
Absorption: Readily absorbed from GI tract. Peak plasma concentration: 1-4 hr.
Distribution: Protein binding: 85-90%. Diffuses readily into extracellular fluid. CSF concentration is 1/3 that of blood. Crosses placenta and into breast milk.
Excretion: Excreted rapidly in urine. Half life: 5-8 hr.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Sulfafurazole from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in